India, June 23 -- French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that a new peer-reviewed data provide strong evidence supporting Masitinib's potential for the treatment of alzheimers disease through a dual mechanism of cognitive enhancement and neuroprotection.
The study is from an independent research team based in China, Guangdong Pharmaceutical University and Sun Yat-sen University. In the study, researchers used a well-established mouse model that mimics the cognitive and behavioral symptoms of human sporadic Alzheimers disease or sAD.
The new evidence shows that masitinib offers a promising new approach to treating Alzheimers disease, specifically the most common form, sporadic Alzheimers disease, which acco...